Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
SELLAS Life Sciences Group (SLS)
NASDAQ:SLS
RESEARCH TOOLSreports
Holding SLS?
Track your performance easily
SLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.50 - $1.90
Previous Close$1.3
Volume413.14K
Average Volume (3M)738.55K
Market Cap
$83.63M
Enterprise Value$75.22M
Total Cash (Recent Filing)$9.10M
Total Debt (Recent Filing)$692.00K
Price to Earnings (P/E)―
Beta2.60
Next Earnings
Nov 14, 2024EPS Estimate
-$0.13Last Dividend Ex-Date
Apr 27, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding64,332,498
10 Day Avg. Volume405,601
30 Day Avg. Volume738,552
Standard Deviation0.32
R-Squared0.16
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)8.40
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.20
Forecast
1Y Price Target
$4.00Price Target Upside217.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
SELLAS Life Sciences Group News
Ownership Overview
7.09% Insiders
3.34% Mutual Funds
6.44% Other Institutional Investors
83.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLS FAQ
What was SELLAS Life Sciences Group’s price range in the past 12 months?
SELLAS Life Sciences Group lowest stock price was $0.50 and its highest was $1.90 in the past 12 months.
What is SELLAS Life Sciences Group’s market cap?
Currently, no data Available
When is SELLAS Life Sciences Group’s upcoming earnings report date?
SELLAS Life Sciences Group’s upcoming earnings report date is Nov 14, 2024 which is in 55 days.
How were SELLAS Life Sciences Group’s earnings last quarter?
SELLAS Life Sciences Group released its earnings results on Aug 13, 2024. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.173 by $0.043.
Is SELLAS Life Sciences Group overvalued?
According to Wall Street analysts SELLAS Life Sciences Group’s price is currently Undervalued.
Does SELLAS Life Sciences Group pay dividends?
SELLAS Life Sciences Group pays a Notavailable dividend of $7025.8 which represents an annual dividend yield of N/A. See more information on SELLAS Life Sciences Group dividends here
What is SELLAS Life Sciences Group’s EPS estimate?
SELLAS Life Sciences Group’s EPS estimate is -$0.13.
How many shares outstanding does SELLAS Life Sciences Group have?
SELLAS Life Sciences Group has 64,332,500 shares outstanding.
What happened to SELLAS Life Sciences Group’s price movement after its last earnings report?
SELLAS Life Sciences Group reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.173. Following the earnings report the stock price went up 0.84%.
Which hedge fund is a major shareholder of SELLAS Life Sciences Group?
Among the largest hedge funds holding SELLAS Life Sciences Group’s share is Highbridge Capital Management LLC. It holds SELLAS Life Sciences Group’s shares valued at N/A.
---
SELLAS Life Sciences Group Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (217.46% Upside)
$4.00 (217.46% Upside)
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.25%
12-Months-Change
Fundamentals
Return on Equity
-888.06%
Trailing 12-Months
Asset Growth
-18.57%
Trailing 12-Months
Company Description
SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutics for cancer indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. Its products include galinpepimut-S and nelipepimut-S. The company was founded on April 3, 2006 and is headquartered in New York, NY.
---
SLS Stock 12 Month Forecast
Average Price Target
$4.00
▲(217.46% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Aileron Therapeutics
―
Cardiff Oncology
―
Kintara Therapeutics
―
Best Analysts Covering SLS
1 Year
1 Year Success Rate
8/18 ratings generated profit
1 Year Average Return
-6.16%
reiterated a buy rating last month
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -6.16% per trade.
---